Yuhan and Cyrus Therapeutics signed an agreement for Joint Research on Anti-Cancer Target Therapeutics 

Share This Post

Yuhan announced that it has signed an MOU with Cyrus Therapeutics to develop a small molecule anti-cancer target therapy.

Cyrus Therapeutics is a Korean biotechnology company with small molecule therapeutics and targeted proteolysis (TPD) technology that degrades protein and removes cancer cells.

Through the agreement, the two companies plan to cooperate in the fields of basic research on anti-cancer drug development, development of new anti-cancer drug candidates, technology transfer and commercialization using Cyrus Therapeutics’ technologies.

유한양행-사이러스테라퓨틱스 “항암 표적치료제 공동연구”

More To Explore